脑脊液ctDNA分析指导弥漫性胶质瘤分子重分类
本研究收集43例不同类型胶质瘤患者的脑脊液样本,用600基因NGS panel检测ctDNA。26/43(60%)样本检出突变,结合临床参数可依据2021 WHO分类识别特定CNS肿瘤类型,使3例患者获得重分类,且CSF-ctDNA检出与影像特征显著相关。
要点
- 脑脊液ctDNA检测在60%(26/43)胶质瘤患者中可检出突变。
- CSF-ctDNA结合临床参数可辅助2021 WHO分类并重分类患者。
- DNA投入量不足(<30 ng)是突变未检出的主要原因。
核心结论
- 脑脊液ctDNA分析对胶质瘤患者的评估和重分类具有潜在临床价值。
研究设计与样本
- 收集43例不同类型胶质瘤患者的脑脊液样本(0.4-5 mL),采用靶向600个癌症相关基因的NGS panel检测ctDNA。
主要发现
- 26/43(60%)样本检出突变,其中SNV 19/43(44%)、CNV 11/43(25%)、移码突变8/43(18.6%)、融合1/43(2.3%)。
- 17例未检出突变,其中15/17(88%)样本DNA投入量不足(<30 ng)。
- 检出诊断性变异包括IDH1突变(3/6 IDH突变型胶质瘤)、TERTp突变(7/29胶质母细胞瘤)、EGFR扩增(5/29胶质母细胞瘤)、H3-3A突变(4/4儿童高级别胶质瘤)。
- 结合其他临床参数,依据2021 WHO CNS肿瘤分类识别特定肿瘤类型,使3例患者获得重分类。
- CSF-ctDNA检出与影像特征存在显著关联。
临床怎么用
- 对胶质瘤患者可考虑脑脊液ctDNA检测辅助分子诊断与分型。
- 检测时需注意DNA投入量,<30 ng可能影响突变检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a critical need for better strategies to diagnose and monitor patients with gliomas. Liquid biopsies are less invasive than tissue biopsies and are amenable to serial collection at multiple timepoints. However, the analysis of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) from patients with gliomas remains underutilized in clinical practice due to technical challenges. METHODS: We collected CSF samples from 43 patients with various types of gliomas and evaluated ctDNA derived from CSF with a next generation sequencing (NGS) panel interrogating 600 cancer-related genes. RESULTS: Total cell-free DNA (cfDNA) concentration obtained from CSF (0.4-5 mL) ranged from 0.09 to 60 ng/µL. Mutations were detected in 26/43 (60%) samples including 19/43 (44%) with single nucleotide variants (SNV), 11/43 (25%) with copy number variants (CNV), 8/43 (18.6%) with frameshifts and 1/43 with fusion (2.3%). Mutations were not identified in 17 CSF samples, and most of these samples (15/17; 88%) had suboptimal DNA input (< 30 ng). We identified diagnostic alterations in CSF including mutations in IDH1 (3/6 IDH-mutant gliomas), TERTp (7/29 glioblastomas), EGFR amplification (5/29 glioblastomas), and H3-3 A (4/4 pediatric high-grade gliomas). Some of these mutations, in combination with other clinical parameters, allowed us to identify specific CNS tumor types based on the 2021 World Health Organization (WHO) classification of CNS tumors, resulting in the reclassification of 3 patients. Furthermore, we observed a significant association between the CSF-ctDNA detection and imaging features. CONCLUSION: This study highlights the potential clinical utility of CSF-ctDNA analysis for evaluating and reclassification of patients with gliomas.
引用
- Arjuna S, Pirhoushiaran M, Bueno A, et al. CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients. J Neurooncol. 2026. PMID: 42168657. doi:10.1007/s11060-026-05623-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。